Genmab — December 2018
-
isatuximab plus VRd https://twitter.com/mohty_ebmt/status/1069613231277191168?s=21
-
-
This study showed that the longer course of daratumumab significantly reduced the risk of the disease progressing compared with the shorter course — and presumably compared with receiving no therapy at all, which is the current standard of care,” Dr. Landgren says. “Daratumumab is safe, with verhttps://www.mskcc.org/blog/advances-myeloma-lymphoma-and-bone-marrow-transplant-announced-2018-ash-meeting
y little toxicity, so there is little apparent downside to giving it for longer periods.” -
Advances in Myeloma, Lymphoma, and Bone Marrow Transplant Announced at the 2018 ASH Meeting | Memorial Sloan Kettering Cancer Center
Learn more about the work of MSK researchers being presented at the 2018 meeting of the American Society of Hematology.
(www.mskcc.org)
-
Nogen, der har noget nyt fra R & D
-
Professor om Genmab's guldklump. " patienterne kan fortsætte på Dara for altid. https://borsen.dk/nyheder/virksomheder/artikel/1/373339/professor_om_genmabs_guldklump_patienterne_kan_fortsaette_i_behandlingen_for_altid.html
-
Noget om RTOR? Ellers kan vi vel skyde en hvid pil efter en hurtig godkendelse?
-
Ja lægerne vil bruge dara i første linie. Det var Saad Uzmanis klare statement. Men Vincent Rajkumar har jo i løbet af ASH givet udtryk for noget andet!
-
Ok. Tak.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind